Atara Biotherapeutics, Pascal Touchon, Ameet Mallik, Rafael Holdings
A veteran in cell therapy and oncology commercialisation
A veteran in cell therapy and oncology commercialisation
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s Navicixizumab
Founded in 2019, the start-up develops digital therapeutics, a therapeutic intervention from the convergence of biology and information technology
Preclinical and early human data indicate BriLife may confer enhanced immunity against Delta variant
The government has recently enhanced the incentive granted to storeowners from existing Rs. 2.50 lakh to Rs. 5.00 lakh given at the rate of 15% of monthly purchases made, subject to a ceiling of Rs. 15,000 per month
Board declares interim dividend of Rs 2 per equity share
The goal for the project is the identification and optimization of anti-viral compounds.
Phase II trial will evaluate the safety and efficacy of ASC40 in patients with moderate to severe acne
Single booster dose at 6 months of NVX-CoV2373 increased wild-type neutralizing antibodies more than 4-fold versus primary vaccination series
Sickle Cell Disease Support Corner developed to create a database of individuals with sickle cell disease
Subscribe To Our Newsletter & Stay Updated